Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Miriam Provost Biography and Net Worth

VP of TransMedics Group

Miriam Provost has over 24 years of experience in Medical Device Regulatory Affairs, including 13 years at the Food and Drug Administration. Prior to joining TransMedics, Dr. Provost was an internationally recognized expert in Regulatory Affairs and provided strategic guidance and tactical support for large and small medical device companies as medical device regulatory consultant. Her expertise stems from 13 years as a reviewer and manager at the Food and Drug Administration where she served in a variety of roles across the Agency, gaining broad knowledge and familiarity with all matters related to FDA policies, procedures and decision-making. Dr. Provost earned a Bachelor’s degree in Chemical Engineering from the University of Dayton and M.S. and Ph.D. degrees in Chemical Engineering from the University of Pennsylvania.

What is Miriam Provost's net worth?: The estimated net worth of Miriam Provost is at least $2.19 million as of December 13th, 2023. Ms. Provost owns 23,820 shares of TransMedics Group stock worth more than $2,193,346 as of April 27th. This net worth evaluation does not reflect any other assets that Ms. Provost may own. Learn More about Miriam Provost's net worth.
How do I contact Miriam Provost?: The corporate mailing address for Ms. Provost and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Miriam Provost's contact information.
Has Miriam Provost been buying or selling shares of TransMedics Group?: Miriam Provost has not been actively trading shares of TransMedics Group during the last quarter. Most recently, Miriam Provost sold 4,122 shares of the business's stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $75.10, for a transaction totalling $309,562.20. Following the completion of the sale, the vice president now directly owns 23,820 shares of the company's stock, valued at $1,788,882. Learn More on Miriam Provost's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), and Miriam Provost (VP). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, TransMedics Group insiders bought shares 1 times. They purchased a total of 2,500 shares worth more than $155,000.00. In the last year, insiders at the sold shares 31 times. They sold a total of 231,712 shares worth more than $18,661,937.87. The most recent insider tranaction occured on April, 17th when CEO Waleed H Hassanein sold 4,000 shares worth more than $380,480.00. Insiders at TransMedics Group own 6.7% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 4/17/2024.

Miriam Provost Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2023	Sell	4,122	$75.10	$309,562.20	23,820
8/31/2023	Sell	2,708	$66.52	$180,136.16	23,611
12/13/2022	Sell	4,315	$62.53	$269,816.95	15,154
12/9/2022	Sell	3,613	$59.00	$213,167.00	12,969

Miriam Provost Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $92.08

$89.99

$92.90

50 Day Range

MA: $82.98

$70.86

$95.65

2 Week Range

Now: $92.08

$36.42

$99.63

Volume

634,992 shs

Average Volume

802,060 shs

Market Capitalization

$3.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad